Open Collections

UBC Faculty Research and Publications

Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma Aicher, Wilhelm K; Korn, M.; Reitnauer, L.; Maurer, F. B; Hennenlotter, J.; Black, Peter C.; Todenhofer, T.; Bedke, J.; Stenzl, A.

Abstract

Background: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue samples of BC stages from pT2 to pT4. Methods: CD276 expression was explored in 4 urothelial cancer cell lines and 4 primary normal urothelial cell populations by quantitative RT-PCR, Western blot and flow cytometry. CD276 was investigated in bladder tumors from 98 patients by immunohistochemistry using a score (0–300) incorporating both, staining intensity and area of CD276 staining. Normal appearing urothelium in the bladder of the same patients served as controls. Results: The urothelial carcinoma cell lines expressed significantly higher levels of CD276 on transcript (p 

Item Metadata

Title
Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma
Creator
Aicher, Wilhelm K; Korn, M.; Reitnauer, L.; Maurer, F. B; Hennenlotter, J.; Black, Peter C.; Todenhofer, T.; Bedke, J.; Stenzl, A.
Contributor
Vancouver Prostate Centre
Publisher
BioMed Central
Date Issued
2021-04-12
Description
Background: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue samples of BC stages from pT2 to pT4. Methods: CD276 expression was explored in 4 urothelial cancer cell lines and 4 primary normal urothelial cell populations by quantitative RT-PCR, Western blot and flow cytometry. CD276 was investigated in bladder tumors from 98 patients by immunohistochemistry using a score (0–300) incorporating both, staining intensity and area of CD276 staining. Normal appearing urothelium in the bladder of the same patients served as controls. Results: The urothelial carcinoma cell lines expressed significantly higher levels of CD276 on transcript (p 
Subject
Urothelial carcinoma; Immune check-point protein; CD276; B7-H3; Bladder tumor stages
Genre
Article
Type
Text
Language
eng
Date Available
2021-04-14
Provider
Vancouver : University of British Columbia Library
Rights
Attribution 4.0 International (CC BY 4.0)
DOI
10.14288/1.0396701
URI
http://hdl.handle.net/2429/77781
Affiliation
Other UBC; Non UBC
Citation
BMC Urology. 2021 Apr 12;21(1):60
Publisher DOI
10.1186/s12894-021-00829-0
Peer Review Status
Reviewed
Scholarly Level
Faculty
Copyright Holder
The Author(s)
Rights URI
http://creativecommons.org/licenses/by/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution 4.0 International (CC BY 4.0)